Neurogene Inc. (NGNE) stock
NGNENasdaqPharmaceutical PreparationsFiscal year ends December 31
$23.10−0.20 (-0.86%)
Close on Nov 17, 2026Market cap $462.26MP/E –Yield –
Neurogene total assets
Total assets on the balance sheet at the end of each period.
Neurogene's total assets was $244.36M at Jun 30, 2026. For fiscal 2025 it was $288.60M, down 14.0% from the year before. Over ten years it grew 9.8% a year on average. The highest annual figure on record is $335.73M in fiscal 2024.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $288.60M | -14.0% |
| FY2024 | Dec 31, 2024 | $335.73M | +50.8% |
| FY2023 | Dec 31, 2023 | $222.57M | +103.7% |
| FY2022 | Dec 31, 2022 | $109.27M | -33.1% |
| FY2021 | Dec 31, 2021 | $163.26M | -22.4% |
| FY2020 | Dec 31, 2020 | $210.52M | +43.2% |
| FY2019 | Dec 31, 2019 | $147.02M | +89.4% |
| FY2018 | Dec 31, 2018 | $77.62M | -29.6% |
| FY2017 | Dec 31, 2017 | $110.33M | -28.5% |
| FY2016 | Dec 31, 2016 | $154.38M | +36.2% |
| FY2015 | Dec 31, 2015 | $113.34M | +173.6% |
| FY2014 | Dec 31, 2014 | $41.42M | +164.7% |
| FY2013 | Dec 31, 2013 | $15.65M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $244.36M | -17.8% |
| Q1 FY2026 | Mar 31, 2026 | $263.14M | -16.5% |
| Q4 FY2025 | Dec 31, 2025 | $288.60M | -14.0% |
| Q3 FY2025 | Sep 30, 2025 | $287.83M | +75.4% |
| Q2 FY2025 | Jun 30, 2025 | $297.32M | +65.3% |
| Q1 FY2025 | Mar 31, 2025 | $315.30M | +61.4% |
| Q4 FY2024 | Dec 31, 2024 | $335.73M | +50.8% |
| Q3 FY2024 | Sep 30, 2024 | $164.12M | +83.2% |
| Q2 FY2024 | Jun 30, 2024 | $179.82M | +91.3% |
| Q1 FY2024 | Mar 31, 2024 | $195.35M | +98.4% |
| Q4 FY2023 | Dec 31, 2023 | $222.57M | +103.7% |
| Q3 FY2023 | Sep 30, 2023 | $89.59M | -29.2% |
| Q2 FY2023 | Jun 30, 2023 | $94.01M | -31.4% |
| Q1 FY2023 | Mar 31, 2023 | $98.46M | -34.0% |
| Q4 FY2022 | Dec 31, 2022 | $109.27M | -33.1% |
| Q3 FY2022 | Sep 30, 2022 | $126.58M | -28.1% |
| Q2 FY2022 | Jun 30, 2022 | $137.02M | -26.7% |
| Q1 FY2022 | Mar 31, 2022 | $149.13M | -25.5% |
| Q4 FY2021 | Dec 31, 2021 | $163.26M | -22.4% |
| Q3 FY2021 | Sep 30, 2021 | $175.93M | -20.6% |
| Q2 FY2021 | Jun 30, 2021 | $187.02M | +28.7% |
| Q1 FY2021 | Mar 31, 2021 | $200.10M | +30.7% |
| Q4 FY2020 | Dec 31, 2020 | $210.52M | +43.2% |
| Q3 FY2020 | Sep 30, 2020 | $221.69M | +217.6% |
| Q2 FY2020 | Jun 30, 2020 | $145.32M | +97.1% |
| Q1 FY2020 | Mar 31, 2020 | $153.05M | +102.9% |
| Q4 FY2019 | Dec 31, 2019 | $147.02M | +89.4% |
| Q3 FY2019 | Sep 30, 2019 | $69.79M | -20.5% |
| Q2 FY2019 | Jun 30, 2019 | $73.74M | -29.4% |
| Q1 FY2019 | Mar 31, 2019 | $75.43M | -21.1% |
| Q4 FY2018 | Dec 31, 2018 | $77.62M | -29.6% |
| Q3 FY2018 | Sep 30, 2018 | $87.81M | -27.8% |
| Q2 FY2018 | Jun 30, 2018 | $104.43M | -21.7% |
| Q1 FY2018 | Mar 31, 2018 | $95.62M | -33.3% |
| Q4 FY2017 | Dec 31, 2017 | $110.33M | -28.5% |
| Q3 FY2017 | Sep 30, 2017 | $121.60M | -25.9% |
| Q2 FY2017 | Jun 30, 2017 | $133.28M | – |
| Q1 FY2017 | Mar 31, 2017 | $143.33M | – |
| Q4 FY2016 | Dec 31, 2016 | $154.38M | – |
| Q3 FY2016 | Sep 30, 2016 | $164.07M | – |
See a number that looks wrong?